{"id":"clonidine-oral-liquid-product","safety":{"commonSideEffects":[{"rate":"40","effect":"Dry mouth"},{"rate":"35","effect":"Drowsiness/sedation"},{"rate":"16","effect":"Dizziness"},{"rate":"10","effect":"Constipation"},{"rate":"10","effect":"Headache"},{"rate":"8","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Clonidine binds to alpha-2 adrenergic receptors in the central nervous system, particularly in the locus coeruleus, which decreases the release of norepinephrine and reduces overall sympathetic outflow. This leads to decreased heart rate, blood pressure, and peripheral vascular resistance. The drug also has peripheral alpha-2 effects that contribute to its antihypertensive action.","oneSentence":"Clonidine is an alpha-2 adrenergic agonist that reduces sympathetic nervous system activity by stimulating alpha-2 receptors in the brain and periphery.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:27:39.434Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Attention-deficit/hyperactivity disorder (ADHD)"},{"name":"Opioid withdrawal"}]},"trialDetails":[{"nctId":"NCT04902859","phase":"PHASE4","title":"Clonidine as Pain Relief During ROP Eye Examinations","status":"UNKNOWN","sponsor":"Region Örebro County","startDate":"2022-04-25","conditions":"Retinopathy of Prematurity, Pain, Procedural, Premature Infant Disease","enrollment":50},{"nctId":"NCT04032691","phase":"EARLY_PHASE1","title":"PET Study of a2a Agonist Effects on the Ventricular CSF Clearance of [11C]Butanol","status":"WITHDRAWN","sponsor":"Weill Medical College of Cornell University","startDate":"2019-08-27","conditions":"Healthy Volunteers","enrollment":""},{"nctId":"NCT04030572","phase":"EARLY_PHASE1","title":"Feasibility of Administering Clonidine as a Pharmacological Challenge in Imaging Studies","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2019-12-10","conditions":"Neuro-Degenerative Disease, Cancer","enrollment":3}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Clonidine Oral Liquid Product","genericName":"Clonidine Oral Liquid Product","companyName":"Region Örebro County","companyId":"region-rebro-county","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Clonidine is an alpha-2 adrenergic agonist that reduces sympathetic nervous system activity by stimulating alpha-2 receptors in the brain and periphery. Used for Hypertension, Attention-deficit/hyperactivity disorder (ADHD), Opioid withdrawal.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}